Talaris Therapeutics Stock

talaristx.comHealthcare / BioTech & PharmaFounded: 1900Funding to Date: $100MM

Talaris Therapeutics is a late-clinical stage biotechnology company developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders.

Register To Buy and Sell Shares

For more details on financing and valuation for Talaris Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Talaris Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Talaris Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Nancy Krieger MD
Chief Medical Officer
Francois Nader
Chairman
Suzanne Ildstad MD
Founder, Board Member & Chief Scientific Officer
Scott Requadt JD
Chief Executive Officer & Board Member

Board Members

Geoff MacKay
Sandip Agarwala
Longitude Capital
Mark McDade
Qiming Venture Partners
Scott Requadt JD
Suzanne Ildstad MD
Francois Nader
Nicholas Galakatos Ph.D
Blackstone Life Sciences

Frequently Asked Questions About Talaris Therapeutics’ Stock

plusminus
Can you buy Talaris Therapeutics’ stock?
Talaris Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy Talaris Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Talaris Therapeutics’ stock?
Yes, you can sell stock of a private company like Talaris Therapeutics. Forge can help you sell your Talaris Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Talaris Therapeutics’ stock price?
Talaris Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Talaris Therapeutics’ private market stock price with Forge Data.
plusminus
What is Talaris Therapeutics’ stock ticker symbol?
Talaris Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Talaris Therapeutics, Inc. Announces $100M Series A Financing to Advance Its Novel, Allogeneic Cell Therapy Through Late-Stage Clinical Development
The series A funding will be used to advance Talaris' proprietary, one-time, allogeneic cell therapy, FCR001, into later-stage clinical development.
Talaris Therapeutics Raises $100M in Series A Financing | FinSMEs
Talaris Therapeutics, which develops cell therapies with potential to eliminate chronic immunosuppression for organ transplant recipients, raised $100m
Updated on: Jun 15, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.